Nurix Therapeutics (NRIX) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$592.9 million.
- Nurix Therapeutics' Enterprise Value rose 273.01% to -$592.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$592.9 million, marking a year-over-year increase of 273.01%. This contributed to the annual value of -$592.9 million for FY2025, which is 273.01% up from last year.
- Nurix Therapeutics' Enterprise Value amounted to -$592.9 million in Q4 2025, which was up 273.01% from -$428.8 million recorded in Q3 2025.
- Nurix Therapeutics' 5-year Enterprise Value high stood at -$244.0 million for Q1 2024, and its period low was -$609.6 million during Q4 2024.
- Its 5-year average for Enterprise Value is -$372.4 million, with a median of -$326.5 million in 2021.
- In the last 5 years, Nurix Therapeutics' Enterprise Value soared by 2485.67% in 2023 and then plummeted by 12528.52% in 2025.
- Nurix Therapeutics' Enterprise Value (Quarter) stood at -$295.7 million in 2021, then dropped by 4.54% to -$309.1 million in 2022, then rose by 6.87% to -$287.9 million in 2023, then tumbled by 111.73% to -$609.6 million in 2024, then rose by 2.73% to -$592.9 million in 2025.
- Its last three reported values are -$592.9 million in Q4 2025, -$428.8 million for Q3 2025, and -$485.8 million during Q2 2025.